A groundbreaking study emerging from the Neuroscience Institute and Department of Psychiatry at Mass General Brigham has revealed compelling evidence that personalized brain imaging can significantly enhance the efficacy of accelerated transcranial magnetic stimulation (aTMS) in the treatment of depression. Published recently in JAMA Psychiatry, this randomized clinical trial challenges the conventional scalp-based targeting methods for TMS, proposing a more individualized, connectivity-driven approach that may revolutionize therapeutic protocols for treatment-resistant depression.
Transcranial magnetic stimulation, a non-invasive neuromodulation technique, uses magnetic pulses to influence neural activity in specific brain regions. Since receiving FDA approval in 2008 for major depressive disorder, TMS has grown in clinical utility, particularly for patients unresponsive to traditional pharmacological and psychotherapeutic interventions. Historically, determining the target site for TMS has relied on surface anatomical landmarks on the scalp, which serve as proxies for underlying brain structures. While pragmatically sound and easily accessible for widespread clinical use, this traditional approach lacks customization to the patient’s unique brain circuitry, potentially limiting therapeutic gains.
The innovation introduced by this study lies in leveraging functional magnetic resonance imaging (fMRI) to identify individualized treatment targets based on resting-state functional connectivity. This imaging modality measures synchronized activity patterns amongst disparate brain regions while subjects are at rest. By parsing these connectivity networks, the research team pinpointed precise loci within the brain circuits implicated in depression, thereby refining the spatial accuracy of stimulation. This neuroimaging foundation enables a more tailored intervention that accounts for the heterogeneity of depression at the circuit level.
Of particular note is the application of accelerated TMS (aTMS), which compresses multiple treatment sessions into a single day, thereby shortening the overall treatment course from several weeks to a mere week. This intensification not only improves patient convenience but may enhance neurobiological receptivity to stimulation by delivering more frequent pulses within a condensed timetable. The study set out to compare the clinical outcomes of aTMS when targets were defined by fMRI connectivity versus the established scalp-based targeting.
The trial enrolled 40 adult participants with moderate to severe treatment-resistant major depression, spanning a broad age range of 22 to 80 years. Each individual underwent pre-treatment fMRI scanning to delineate functional connectivity profiles. Subsequently, subjects were randomized to receive aTMS directed either at their individualized connectivity-based target or the conventional scalp-based target. Crucially, both patients and clinical raters were blinded to group assignments to mitigate bias.
One month post-treatment assessments revealed that the group receiving connectivity-guided aTMS demonstrated significantly greater alleviation of depressive symptoms compared to their scalp-based counterparts. These improvements were quantified using the Montgomery-Åsberg Depression Rating Scale (MADRS), a gold-standard clinician-administered instrument that sensitively captures changes in depression severity. Furthermore, the response rate — defined by clinically meaningful symptom reduction — was markedly higher in the connectivity group, with 80% responding versus 60% in the traditional targeting group, underscoring the potential clinical advantage of imaging-informed intervention.
This research builds upon prior explorations led by Joseph Taylor and colleagues, including investigations into imaging-based modulation of anxiety circuits within depressive populations, as recently reported in Molecular Psychiatry. These cumulative findings lend prospective support to the concept that precision neuroimaging can transcend theoretical neuroscience and play a direct role in augmenting therapeutic outcomes.
Taylor emphasizes the significance of closing the gap between neuroimaging research and tangible clinical benefit. Historically, the complexity and additional cost associated with imaging have created barriers to its routine clinical adoption for TMS guidance. This study represents a crucial step toward justifying such investment by empirically demonstrating a quantifiable benefit above conventional practice, a vital incentive for healthcare providers and payers considering integration of this technology.
Despite the promising results, the authors acknowledge particular study limitations, including the modest sample size and single-center study design, which may affect generalizability. They advocate for larger, multi-site trials to validate these early findings and explore durability of treatment effects over extended follow-up periods. Broadening the participant demographics will also be essential to ascertain the utility of connectivity-based targeting across diverse patient populations and varying clinical subtypes of depression.
This trial’s implications extend beyond depression, suggesting that functional brain imaging could inform individualized treatment strategies for a range of psychiatric disorders treatable by neuromodulation, including anxiety, obsessive-compulsive disorder, and post-traumatic stress disorder. As aTMS and neuroimaging technologies continue to evolve and become more accessible, the integration of connectivity-guided targeting holds promise for ushering in a new era of personalized psychiatry grounded in neurobiological precision.
In conclusion, the Mass General Brigham team’s randomized controlled trial provides compelling evidence that connectivity-based targeting via functional MRI can substantially enhance the antidepressant impact of accelerated TMS treatment in individuals with refractory depression. This approach offers a paradigm shift toward precision-guided neuromodulation, with the potential to improve patient outcomes and redefine clinical standards for brain stimulation therapies in psychiatric care.
Subject of Research: People
Article Title: Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial
Web References:
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1100
https://www.massgeneralbrigham.org/en/about/neuroscience-institute
https://www.massgeneralbrigham.org/en/about/complex-psychiatric-care
References:
Taylor, J. et al. “Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial,” JAMA Psychiatry, DOI: 10.1001/jamapsychiatry.2026.1100
Keywords:
Depression, Transcranial magnetic stimulation, Accelerated TMS, Functional magnetic resonance imaging, Functional connectivity, Neuroimaging-guided neuromodulation, Treatment-resistant depression, Personalized psychiatry, Montgomery-Åsberg Depression Rating Scale
Tags: accelerated transcranial magnetic stimulationadvanced depression treatment methodsaTMS clinical trialsbrain connectivity and mental healthfunctional MRI in psychiatryindividualized TMS targetingneuromodulation techniques for depressionnon-invasive brain stimulationpersonalized brain imaging for depressionpersonalized psychiatry interventionsresting-state functional connectivitytreatment-resistant depression therapies
